IL181450A0 - Modulators of hepatocyte growth factor activator - Google Patents

Modulators of hepatocyte growth factor activator

Info

Publication number
IL181450A0
IL181450A0 IL181450A IL18145007A IL181450A0 IL 181450 A0 IL181450 A0 IL 181450A0 IL 181450 A IL181450 A IL 181450A IL 18145007 A IL18145007 A IL 18145007A IL 181450 A0 IL181450 A0 IL 181450A0
Authority
IL
Israel
Prior art keywords
modulators
growth factor
hepatocyte growth
factor activator
activator
Prior art date
Application number
IL181450A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL181450A0 publication Critical patent/IL181450A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL181450A 2004-10-04 2007-02-20 Modulators of hepatocyte growth factor activator IL181450A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61565704P 2004-10-04 2004-10-04
PCT/US2005/036300 WO2006042173A2 (en) 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator

Publications (1)

Publication Number Publication Date
IL181450A0 true IL181450A0 (en) 2007-07-04

Family

ID=36148972

Family Applications (1)

Application Number Title Priority Date Filing Date
IL181450A IL181450A0 (en) 2004-10-04 2007-02-20 Modulators of hepatocyte growth factor activator

Country Status (15)

Country Link
US (4) US20060147451A1 (OSRAM)
EP (1) EP1809673B1 (OSRAM)
JP (2) JP4937127B2 (OSRAM)
KR (1) KR101252306B1 (OSRAM)
CN (1) CN101035810B (OSRAM)
AU (1) AU2005294146B2 (OSRAM)
BR (1) BRPI0515670A (OSRAM)
CA (1) CA2577598C (OSRAM)
ES (1) ES2398528T3 (OSRAM)
IL (1) IL181450A0 (OSRAM)
NO (1) NO20072302L (OSRAM)
NZ (1) NZ553327A (OSRAM)
RU (1) RU2418004C2 (OSRAM)
WO (1) WO2006042173A2 (OSRAM)
ZA (1) ZA200701789B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
CN101652389A (zh) * 2007-02-09 2010-02-17 健泰科生物技术公司 抗robo4抗体及其用途
EP3130607B1 (en) 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
BR112012009245A2 (pt) * 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
EP2491059B1 (en) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2023172863A1 (en) * 2022-03-07 2023-09-14 Elixiron Immunotherapeutics (hong Kong) Limited Anti-cd36 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2102463A1 (en) * 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US7045602B2 (en) * 2000-12-05 2006-05-16 Mitsubishi Chemical Corporation Specific antibody directed to active hepatocyte growth factor activator and method for using the same
JP4090236B2 (ja) * 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator

Also Published As

Publication number Publication date
EP1809673A2 (en) 2007-07-25
KR101252306B1 (ko) 2013-04-08
EP1809673B1 (en) 2012-11-28
US20090047291A1 (en) 2009-02-19
JP2012025752A (ja) 2012-02-09
KR20070102470A (ko) 2007-10-18
US20110098449A1 (en) 2011-04-28
US7825221B2 (en) 2010-11-02
US20130217862A1 (en) 2013-08-22
CA2577598C (en) 2016-09-20
JP4937127B2 (ja) 2012-05-23
CN101035810A (zh) 2007-09-12
CA2577598A1 (en) 2006-04-20
NO20072302L (no) 2007-06-28
NZ553327A (en) 2010-02-26
HK1105006A1 (en) 2008-02-01
CN101035810B (zh) 2011-04-06
JP2008515918A (ja) 2008-05-15
US8969528B2 (en) 2015-03-03
AU2005294146A1 (en) 2006-04-20
RU2007116806A (ru) 2008-11-10
ES2398528T3 (es) 2013-03-19
JP5554298B2 (ja) 2014-07-23
AU2005294146B2 (en) 2011-09-15
BRPI0515670A (pt) 2008-07-29
WO2006042173A3 (en) 2006-08-17
WO2006042173A2 (en) 2006-04-20
US8399629B2 (en) 2013-03-19
US20060147451A1 (en) 2006-07-06
RU2418004C2 (ru) 2011-05-10
ZA200701789B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
IL181450A0 (en) Modulators of hepatocyte growth factor activator
SI1636190T1 (sl) Stabilni kristal 4-oksokinolinske spojine
IL178564A0 (en) Improved modulators of coagulation factors
PT1786472E (pt) Modulação anti-sentido de expressão de apolipoproteína
IL210693A0 (en) Transcription factor modulating compounds and methods of use thereof
IL176958A0 (en) Compounds and methods of use
EP1773826A4 (en) MODULATORS OF C-MET AND THEIR METHOD OF USE
EP1751124A4 (en) RAF MODULATORS AND METHODS OF USE
IL189975A0 (en) Methods of modulating neurotrophin-mediated activity
PL1802579T3 (pl) Pochodne 3-aryloaminopirydynowe
ZA200508562B (en) Controlled manipulation of characters
IL179917A0 (en) Methods and compositions for modulating hepatocyte growth factor activation
EP1817277A4 (en) PHENYL DERIVATIVES AND METHOD OF USE
ZA200705561B (en) Stabilisation of radiopharmaceutical precursors
EP1597366A4 (en) MODULATION OF THE EXPRESSION OF THE INSULINARY GROWTH FACTOR I-RECEPTOR
SI1682537T1 (sl) Modulatorji celularne adhezije
IL179199A0 (en) Modulation of wrn-mediated telomere-initiated cell signaling
GB0404487D0 (en) Use of enzyme
ZA200606687B (en) Oxydecahydronaphthalene modulators of HM74
ZA200608490B (en) Method of modulating vascularization
GB0510501D0 (en) Display of operational instructions
IL190408A0 (en) Hepatocyte growth factor receptor splice variants and methods of using same
PL114847U1 (en) Magnetic activator
PL114848U1 (en) Magnetic activator
PL114849U1 (en) Magnetic activator